Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Targeting wild-type and mutationally activated FGFR4 in rhabdomyosarcoma with the inhibitor ponatinib (AP24534).

PloS one - 1 Jan 2013

Li Samuel Q, Cheuk Adam T, Shern Jack F, Song Young K, Hurd Laura, Liao Hongling, Wei Jun S, Khan Javed

Abstract excerpt

Rhabdomyosarcoma (RMS) is the most common childhood soft tissue sarcoma. Despite advances in modern therapy, patients with relapsed or metastatic disease have a very poor clinical prognosis. Fibroblast Growth Factor Receptor 4 (FGFR4) is a cell surface tyrosine kinase receptor that is involved in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cell Cycle
Share to Drug Resistance, Neoplasm
Share to Imidazoles

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Pyridazines

Share to Receptor, Fibroblast Growth Factor, Type 4

Share to Rhabdomyosarcoma

Share to STAT3 Transcription Factor

Share to Tumor Burden

Source

Open in PubMed Open full text

Identifiers

PMID: 24124571
DOI: 10.1371/journal.pone.0076551
PMCID: PMC3790700

Genes

FGFR4
STAT3

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-24124571-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Targeting wild-type and mutationally activated FGFR4 in rhabdomyosarcoma with the inhibitor ponatinib (AP24534).PMID 24124571Read ↗

Functional screening of FGFR4-driven tumorigenesis identifies PI3K/mTOR inhibition as a therapeutic strategy in rhabdomyosarcoma.Semantic proximity Read ↗

Identification of FGFR4-activating mutations in human rhabdomyosarcomas that promote metastasis in xenotransplanted models.Semantic proximity Read ↗

FGFR4 Blockade Exerts Distinct Antitumorigenic Effects in Human Embryonal versus Alveolar RhabdomyosarcomaSemantic proximity Read ↗

Ponatinib suppresses the development of myeloid and lymphoid malignancies associated with FGFR1 abnormalities.Semantic proximity Read ↗

Ponatinib (AP24534), a multitargeted pan-FGFR inhibitor with activity in multiple FGFR-amplified or mutated cancer models.Semantic proximity Read ↗

Fibroblast growth factor receptor signaling in hereditary and neoplastic disease: biologic and clinical implications.Semantic proximity Read ↗

Novel Regulatory Factors and Small-Molecule Inhibitors of FGFR4 in CancerSemantic proximity Read ↗

Ponatinib as targeted therapy for FGFR1 fusions associated with the 8p11 myeloproliferative syndromeSemantic proximity Read ↗

Aberrant CDK4 Amplification in Refractory Rhabdomyosarcoma as Identified by Genomic ProfilingSemantic proximity Read ↗

Novel FGFR inhibitor ponatinib suppresses the growth of non-small cell lung cancer cells overexpressing FGFR1Semantic proximity Read ↗

Cell-Based Small-Molecule Compound Screen Identifies Fenretinide as Potential Therapeutic for Translocation-Positive RhabdomyosarcomaSemantic proximity Read ↗

High-Throughput Drug Screening Identifies Pazopanib and Clofilium Tosylate as Promising Treatments for Malignant Rhabdoid TumorsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.